Panel Discussion - December 5th, 2017

BIOPHARMA CONSORTIUM WITH DLA PIPER PRESENTS:

Beyond the Hype & Avoiding the Pitfalls: Strength and Weakness of BIG DATA in Healthcare & Biotech

PROGRAM OVERVIEW:
We hear a lot of hype about what big data and analytic tools such as AI, machine learning, deep learning and neural networks can bring to healthcare. But let's talk about what's happening right now.  Where are these tools being used?  Where are they having the most significant impact and what areas face greater challenges and may lag behind?

Join BPC for a panel discussion of real-world examples of big data analysis and applications.  We will examine how these new tools are being applied to drug discovery, in clinical trials, in the clinical setting and by healthcare providers.  The panelists will examine the variety of data sources and the different challenges each bring when applied to different sectors of the healthcare and biotechnology ecosystem.  For areas that to date have presented greater challenges, the panel will discuss applicable solutions they have enlisted to help move these areas along.

DATE: December 5, 2017
LOCATION: DLA Piper | 2000 University Ave, Palo Alto, CA 94303
AGENDA:
5:00pm | Registration & Networking  
6:00pm | Panel event – Q&A
7:15pm  | Networking
8pm      | Close

PRICING:
$25 for early registration thru Fri Nov 17
$30 for pre-registration thru Mon Dec 4
$40 for walk ins

REGISTRATIONhttp://bpcdec2017event.eventzilla.net

BIOGRAPHIES:
Gini Deshpande, Ph.D. (Panelist) is the founder and CEO of NuMedii, a next generation biopharma company that uses big data, artificial intelligence and systems biology to rapidly discover precision therapeutics.
As CEO, Gini structured the critical partnerships with several large pharma companies and raised the initial rounds of financing.  Prior to NuMedii, she helped companies identify optimal markets and whole product solutions for their ground breaking technologies, including Affymetrix (acquired by Thermo Fisher) and iPierian (acquired by Bristol-Myers Squibb).  Prior to that, Gini led innovation at Children's Hospital Boston, the world’s leading pediatric hospital, focused on the creation of new devices for the tiniest of patients. Gini has helped commercialize early stage technologies in research tools, diagnostics and therapeutics and has closed licensing deals worth several million. Gini received her Masters in Science from the University of Pune (India), her PhD in Biological Sciences from Purdue University, and did post-doctoral work at the Massachusetts General Hospital.

Tara English, MBA (Panelist) leads Technology Strategy & Partnerships at Kaiser Permanente National IT.  
The partnerships function builds relationships with leading technology organizations to introduce and scale transformational platforms in healthcare.  Areas of focus include analytics, remote monitoring, and transportation. 
Within analytics, Tara has worked across diverse topics, including healthbots, event prediction, process automation, speech-to-text, and image classification.  She collaborates with subject matter experts across Kaiser Permanente to identify and prioritize use cases and value potential, build executive sponsorship, plan operationalization of new technologies, and deliver results from key collaborations. Tara received her Masters in Business Administration from UC Berkeley Haas and undergraduate degree from Northwestern University.

Ivana Schnur, M.D., Ph.D. (Panelist) is the Co-Founder and Chief Medical Officer of Sensely, the breakthrough “virtual nurse” that guides patients through the initial triage process through the use of artificial intelligence.   Using smart machine learning and connection to a clinical hub, Sensely’s nurse Olivia directs patients either to a live nurse, schedules a GP appointment, locates clinical services, or gets medical information and advice all while keeping their doctor informed.  Dr. Schnur brings a unique combination of clinical knowledge, product insight, marketing and business development to power the transformation of clinical workflows in scalable, quantifiable and compassionate ways using Sensely technology.
Prior to co-founding Sensely, Dr. Schnur worked at several early stage startups bringing extensive experience in the design of clinical protocols and immersive interfaces, including the application of virtual technology in the clinical settings.  In 2009 she co-founded InWorld Solutions, the pioneering avatar-based virtual reality platform that assists clinical psychologists in behavioral modifications and other clinical modalities. 
Ivana Schnur’s background includes a M.D. from Charles University in Prague, scholarship work at Harvard and Georgetown University Medical Schools, and a Ph.D. in clinical psychology from Institute of Transpersonal Psychology in Palo Alto, California. She entered the startup world through her graduate work on patient engagement and compliance as it relates to quality of life in patients with PTSD and terminal diagnoses.

Mary Wheeler, Ph.D., MBA (Panelist) is the Chief Business Officer of SirenasMD a drug discovery biotech company that applies big data techniques to develop novel drugs inspired by nature. sirenasmd.com
Mary has over 15 years of experience in M&A, licensing and investing in biopharmaceutical companies and related businesses that enable therapeutics.  She has worked in M&A, licensing and corporate development for Johnson & Johnson, Pfizer and Forest Labs (now Allergan). More recently, Mary has advised and held leadership roles in a number of mainly seed and series A therapeutics and health tech companies. She also invests in therapeutics companies using an AngelList Syndicate and is an outside technical consultant for the Gates Foundation.  
Mary received her Ph.D. from Princeton and an MBA from the MIT Sloan School of Management. She is a Kauffman Fellow.

Erica Pascal, Ph.D. Esq. (Moderator) is the Founder of Ingensity IP, a venture dedicated to helping life sciences companies design and implement intellectual property strategy.
Erica is a hybrid scientist-lawyer.  She did her scientific training at MIT and UC Berkeley in the areas of molecular biology and biochemistry.  After 15 years in science, including 8 years in the biotech industry, she returned to school-life to get her law degree.  She then spent almost 10 years at DLA Piper working on IP matters with pharmaceutical, medical device and diagnostic companies. Her areas of experience include patent litigation, licensing, IP due diligence, false advertising and trade secret protection. 
In July of this year, Erica founded Ingensity IP as a new model for working with life science companies, particularly start-ups and their investors.  Ingensity IP works with clients to create IP strategy that is aligned and attuned with their business plans and goals.